vs
ANI PHARMACEUTICALS INC（ANIP）与CSW INDUSTRIALS, INC.（CSW）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是CSW INDUSTRIALS, INC.的1.1倍（$247.1M vs $233.0M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 4.4%，领先6.7%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 20.3%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $22.7M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 5.1%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
ANIP vs CSW — 直观对比
营收规模更大
ANIP
是对方的1.1倍
$233.0M
营收增速更快
ANIP
高出9.3%
20.3%
净利率更高
ANIP
高出6.7%
4.4%
自由现金流更多
ANIP
多$6.4M
$22.7M
两年增速更快
ANIP
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $233.0M |
| 净利润 | $27.5M | $10.3M |
| 毛利率 | — | 39.7% |
| 营业利润率 | 14.1% | 7.4% |
| 净利率 | 11.1% | 4.4% |
| 营收同比 | 29.6% | 20.3% |
| 净利润同比 | 367.5% | -61.9% |
| 每股收益（稀释后） | $1.14 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPCSW
| Q4 25 | $247.1M | $233.0M | ||
| Q3 25 | $227.8M | $277.0M | ||
| Q2 25 | $211.4M | $263.6M | ||
| Q1 25 | $197.1M | $230.5M | ||
| Q4 24 | $190.6M | $193.6M | ||
| Q3 24 | $148.3M | $227.9M | ||
| Q2 24 | $138.0M | $226.2M | ||
| Q1 24 | $137.4M | $210.9M |
净利润ANIPCSW
| Q4 25 | $27.5M | $10.3M | ||
| Q3 25 | $26.6M | $40.7M | ||
| Q2 25 | $8.5M | $40.9M | ||
| Q1 25 | $15.7M | $35.1M | ||
| Q4 24 | $-10.3M | $26.9M | ||
| Q3 24 | $-24.2M | $36.1M | ||
| Q2 24 | $-2.3M | $38.6M | ||
| Q1 24 | $18.2M | $31.8M |
毛利率ANIPCSW
| Q4 25 | — | 39.7% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 43.8% | ||
| Q1 25 | — | 44.2% | ||
| Q4 24 | — | 41.4% | ||
| Q3 24 | — | 45.6% | ||
| Q2 24 | — | 47.5% | ||
| Q1 24 | — | 44.4% |
营业利润率ANIPCSW
| Q4 25 | 14.1% | 7.4% | ||
| Q3 25 | 15.9% | 20.5% | ||
| Q2 25 | 6.6% | 20.8% | ||
| Q1 25 | 13.3% | 19.5% | ||
| Q4 24 | -2.3% | 15.3% | ||
| Q3 24 | -13.8% | 22.6% | ||
| Q2 24 | 3.7% | 24.3% | ||
| Q1 24 | 14.8% | 21.0% |
净利率ANIPCSW
| Q4 25 | 11.1% | 4.4% | ||
| Q3 25 | 11.7% | 14.7% | ||
| Q2 25 | 4.0% | 15.5% | ||
| Q1 25 | 8.0% | 15.2% | ||
| Q4 24 | -5.4% | 13.9% | ||
| Q3 24 | -16.3% | 15.8% | ||
| Q2 24 | -1.7% | 17.1% | ||
| Q1 24 | 13.2% | 15.1% |
每股收益（稀释后）ANIPCSW
| Q4 25 | $1.14 | $0.62 | ||
| Q3 25 | $1.13 | $2.41 | ||
| Q2 25 | $0.36 | $2.43 | ||
| Q1 25 | $0.69 | $2.05 | ||
| Q4 24 | $-0.45 | $1.60 | ||
| Q3 24 | $-1.27 | $2.26 | ||
| Q2 24 | $-0.14 | $2.47 | ||
| Q1 24 | $0.82 | $2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $40.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $1.1B |
| 总资产 | $1.4B | $2.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPCSW
| Q4 25 | $285.6M | $40.2M | ||
| Q3 25 | $262.6M | $31.5M | ||
| Q2 25 | $217.8M | $38.0M | ||
| Q1 25 | $149.8M | $225.8M | ||
| Q4 24 | $144.9M | $213.8M | ||
| Q3 24 | $145.0M | $273.2M | ||
| Q2 24 | $240.1M | $18.9M | ||
| Q1 24 | $228.6M | $22.2M |
总债务ANIPCSW
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $800.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $166.0M |
股东权益ANIPCSW
| Q4 25 | $540.7M | $1.1B | ||
| Q3 25 | $505.8M | $1.1B | ||
| Q2 25 | $436.8M | $1.1B | ||
| Q1 25 | $418.6M | $1.1B | ||
| Q4 24 | $403.7M | $1.0B | ||
| Q3 24 | $405.9M | $1.0B | ||
| Q2 24 | $455.8M | $650.2M | ||
| Q1 24 | $452.0M | $615.7M |
总资产ANIPCSW
| Q4 25 | $1.4B | $2.3B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.0B |
负债/权益比ANIPCSW
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $28.9M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $22.7M |
| 自由现金流率自由现金流/营收 | 11.8% | 9.8% |
| 资本支出强度资本支出/营收 | 0.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.10× | 2.81× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $162.0M |
8季度趋势，按日历期对齐
经营现金流ANIPCSW
| Q4 25 | $30.4M | $28.9M | ||
| Q3 25 | $44.1M | $61.8M | ||
| Q2 25 | $75.8M | $60.6M | ||
| Q1 25 | $35.0M | $27.3M | ||
| Q4 24 | $15.9M | $11.6M | ||
| Q3 24 | $12.5M | $66.8M | ||
| Q2 24 | $17.4M | $62.7M | ||
| Q1 24 | $18.3M | $22.4M |
自由现金流ANIPCSW
| Q4 25 | $29.1M | $22.7M | ||
| Q3 25 | $38.0M | $58.7M | ||
| Q2 25 | $71.8M | $57.7M | ||
| Q1 25 | $32.5M | $22.8M | ||
| Q4 24 | $13.5M | $8.5M | ||
| Q3 24 | $7.7M | $61.3M | ||
| Q2 24 | $13.0M | $59.6M | ||
| Q1 24 | $13.7M | $17.5M |
自由现金流率ANIPCSW
| Q4 25 | 11.8% | 9.8% | ||
| Q3 25 | 16.7% | 21.2% | ||
| Q2 25 | 34.0% | 21.9% | ||
| Q1 25 | 16.5% | 9.9% | ||
| Q4 24 | 7.1% | 4.4% | ||
| Q3 24 | 5.2% | 26.9% | ||
| Q2 24 | 9.4% | 26.3% | ||
| Q1 24 | 10.0% | 8.3% |
资本支出强度ANIPCSW
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 2.7% | 1.1% | ||
| Q2 25 | 1.9% | 1.1% | ||
| Q1 25 | 1.3% | 2.0% | ||
| Q4 24 | 1.3% | 1.6% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 3.2% | 1.4% | ||
| Q1 24 | 3.3% | 2.3% |
现金转化率ANIPCSW
| Q4 25 | 1.10× | 2.81× | ||
| Q3 25 | 1.66× | 1.52× | ||
| Q2 25 | 8.87× | 1.48× | ||
| Q1 25 | 2.23× | 0.78× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 1.85× | ||
| Q2 24 | — | 1.62× | ||
| Q1 24 | 1.00× | 0.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
